Physician profile
Raymond J Ramirez
NPI 1063614840
$14,517.14
in general payments reported to CMS, 2019-2025
39 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $2,153 · 2021: $1,137 · 2022: $2,528 · 2023: $3,344 · 2024: $1,642 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,320 · Consulting Fee: $1,650 · Education: $28.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,319.52 |
| Consulting Fee | $1,650.00 |
| Education | $28.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,676.84 | 2019-2025 | |
| Ucb, INC. | $1,614.59 | 2019-2025 | Bimzelx |
| Abbvie INC. | $1,556.51 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $1,482.00 | 2020 | |
| Sun Pharmaceutical Industries INC. | $844.26 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $800.09 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $794.73 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $490.45 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $462.68 | 2019-2025 | Nemluvio |
| Dermavant Sciences, INC. | $438.06 | 2023-2024 | Vtama |
| Genzyme Corporation | $431.55 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $379.11 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $279.48 | 2019-2025 | Ebglyss, Taltz |
| Mayne Pharma Commercial LLC | $257.43 | 2019-2021 | |
| Pfizer INC. | $247.14 | 2019-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $215.48 | 2021-2025 | Opzelura |
| Organon LLC | $187.53 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $186.39 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $169.52 | 2022-2023 | Keytruda, Lynparza |
| Integra Lifesciences Corporation | $165.69 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Vyne Pharmaceuticals INC. | $137.10 | 2020-2021 | |
| Dermira, INC. | $108.31 | 2019 | |
| Leo Pharma INC. | $98.52 | 2019-2025 | Adbry |
| Genentech USA, INC. | $61.06 | 2021 | |
| Celgene Corporation | $57.93 | 2019 | |
| Arcutis Biotherapeutics, INC. | $56.07 | 2023-2024 | Zoryve |
| Elekta, INC. | $54.47 | 2024 | Elekta Medical Linear Accelerator |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.20 | 2022-2023 | Spevigo |
| Sandoz INC. | $39.32 | 2019-2021 | |
| Icad, INC | $32.18 | 2022-2023 | Axxent Surface Controller |
| Paratek Pharmaceuticals, INC. | $24.02 | 2021 | |
| Promius Pharma LLC | $21.13 | 2019 | |
| Smith+Nephew, INC. | $20.85 | 2022 | |
| Nabriva Therapeutics, Plc | $17.92 | 2021 | |
| Organogenesis INC. | $16.50 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.74 | 2024 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Encore Dermatology INC. | $12.07 | 2019 | |
| Strata Skin Sciences, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.